Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Botanix achieves record prescriptions for Sofdra despite temporary revenue decline

Botanix reported a record volume for Sofdra with 26,684 prescriptions delivered in the quarter and a monthly record in March, while net revenues temporarily fell from $9.1 million to $6.9 million due to the annual reset of deductibles in US health insurance plans. The GTN margin declined temporarily but is expected to normalize in the fourth quarter. The company strengthened its balance sheet with a $45 million capital raise, negotiated payment deferrals for API purchases, and signed a term-sheet agreement with Piramal that could reduce manufacturing costs by an estimated 25–40%. » Mere på de.investing.com
Botanix Pharmaceuticals achieves revenue growth and record prescription deliveries in Q3 2026

Botanix reported a gross revenue of AUD 120 million over the past 12 months and delivered 26,684 prescriptions in Q3. The gross-to-net margin improved from 16% to 19% by quarter-end, and the pro forma cash position is AUD 50.8 million. The stock fell 5% after the release. Management expects further margin improvement in Q4; projected EPS: -0.02 USD (2026) and -0.01 USD (2027), revenue forecasts: 27.71 million USD (2026) and 56.43 million USD (2027). » Mere på de.investing.com
Botanix: Sofdra revenue rises 28%, stock weighed down by higher costs

Botanix reported Q2 FY2026 net revenue of $9.1m, driven by a 24% increase in Sofdra prescriptions versus the prior quarter. The gross-to-net margin improved to 24% but remains below the 30–40% target range. Operating cash outflow rose to $17.2m after expanding the field sales force and higher operating expenses, worrying investors and sending the stock down 6%. Botanix has $31.5m in cash and $14.9m in undrawn credit lines; the challenge remains controlling costs and improving margins toward profitability. » Mere på de.investing.com

Historisk udbytte Udbytte

I 1996 har BOTANIX PHARMACEUTICALS allerede udloddet 88,44 € i udbytte. Den seneste udlodning fandt sted i oktober 1996.

Virksomhedstal

I det seneste kvartal havde BOTANIX PHARMACEUTICALS en omsætning på 10,91 mio. € og et nettoresultat på -22,15 mio. €

(EUR)	juni 2026	YoY
Omsætning	10,91 mio.	-
Bruttofortjeneste	-18,57 mio.	-
Nettoresultat	-22,15 mio.	-
EBITDA	-21,62 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	12,3 mio. €
Antal aktier	1,99 mia.
Højeste/laveste i 52 uger	0,0926 € - 0,00494 €
Udbytte	Nej
Beta	0,90
P/E (PE Ratio)	-0,31
PEG (PEG Ratio)	-0,01
K/I (PB Ratio)	0,38
P/S (PS Ratio)	0,58

Virksomhedsprofil

Botanix Pharmaceuticals Limited er et klinisk fase virksomhed inden for syntetiske cannabinoid-lægemidler, der beskæftiger sig med forskning og udvikling af produkter til dermatologi og antimikrobielle produkter i Australien. Virksomhedens produktpipeline omfatter BTX 1503, en transdermal gelformulering til behandling af svær akne hos voksne og teenagere, som har gennemført kliniske fase II-forsøg; BTX 1801, som har gennemført kliniske fase IIa-forsøg til behandling af staphylococcus aureus og methicillinresistent staphylococcus aureus; BTX 1702, som er i kliniske fase Ib-forsøg til behandling af papulopustuløs rosacea; og BTX 1204A til behandling af atopisk dermatitis. Virksomheden blev stiftet i 1984 og har hovedkontor i North Perth, Australien.